设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

2020 年第 12 期 第 15 卷

埃索美拉唑联合莫沙必利对反流性食管炎患者血清胃泌素和胃蛋白酶原及炎症因子水平的影响

Effect of esomeprazole combined with mosapride on serum gastrin, pepsinogen and inflammatory factor levels in patients with reflux esophagitis

作者:张旭

英文作者:Zhang Xu

单位:浙江医院急诊科,杭州310012

英文单位:Department of Emergency Zhejiang Hospital Hangzhou 310012 China

关键词:反流性食管炎;埃索美拉唑;莫沙必利;胃泌素;胃蛋白酶原;炎症因子

英文关键词:Refluxesophagitis;Esomeprazole;Mosapride;Gastrin;Pepsinogen;Inflammatoryfactors

  • 摘要:
  • 目的 观察埃索美拉唑联合莫沙必利对反流性食管炎患者血清胃泌素和胃蛋白酶原及炎症因子水平的影响。方法 选取20171月至201812月在浙江医院诊治的反流性食管炎患者130例为研究对象。完全随机方法分为对照组和观察组,各65例。对照组给予埃索美拉唑治疗,观察组给予埃索美拉唑联合莫沙必利治疗,2组均治疗2个月。比较2组患者的临床治疗效果,治疗前后血清胃泌素、胃蛋白酶原及炎症因子水平,以及不良反应发生率。结果 观察组总有效率高于对照组[93.8%61/65)比81.5%53/65)],差异有统计学意义(P<0.05)。治疗后2组反酸、烧心、胸骨后疼痛症状评分均较治疗前降低,且观察组低于对照组,差异均有统计学意义(均P<0.05)。治疗后,2组胃蛋白酶原Ⅰ水平均较治疗前升高,且观察组高于对照组[(124.8±12.9)μg/L比(102.9±12.8)μg/L],胃蛋白酶原Ⅱ、胃泌素17、白细胞介素(IL-1β、IL-2IL-6水平均较治疗前降低且观察组低于对照组[(15.2±3.0)μg/L比(20.1±3.0)μg/L、(15.2±2.8pmol/L比(18.1±3.0pmol/L、(33±6ng/L比(46±6ng/L、(31±4ng/L比(42±7ng/L、(28±4ng/L比(40±5ng/L],差异均有统计学意义(均P<0.05)。2组不良反应发生率均为4.6%3/65),差异无统计学意义(P>0.05)。结论 埃索美拉唑联合莫沙必利治疗反流性食管炎临床效果明显,且能显著改善患者血清胃泌素、胃蛋白酶原及炎症因子水平而不增加不良反应。

  • Objective To observe the effect of esomeprazole combined with mosapride on serum gastrin, pepsin and inflammatory factor levels in patients with reflux esophagitis. Methods Totally 130 patients with reflux esophagitis admitted to Zhejiang Hospital from January 2017 to December 2018 were enrolled. The patients were randomly divided into control group and observation group, with 65 cases in each group. The control group received esomeprazole treatment; the observation group received esomeprazole combined with mosapride treatment; both groups were treated for 2 months. The clinical therapeutic effect of the two groups, the levels of serum gastrin, pepsinogen and inflammatory factors before and after treatment and incidence of adverse reactions were compared. Results The total effective rate of observation group was significantly higher than that of the control group93.8%61/65 vs 81.5%53/65)](P<0.05). After treatment, the scores of acid reflux, heartburn, and post-sternal pain in both groups were lower than those before treatment and those in observation group were lower than those in the control group (all P<0.05). After treatment, the level of pepsinogen I in the two groups were higher than those before treatment and that in observation group was higher than that in the control group[(124.8±12.9)μg/L vs 102.9±12.8)μg/L; the levels of pepsinogen , gastrin 17, interleukin (IL)-1β, IL-2 and IL-6 in observation group were lower than those before treatment and those in control group[(15.2±3.0)μg/L vs 20.1±3.0)μg/L, 15.2±2.8pmol/L vs 18.1±3.0pmol/L, 33±6ng/L vs 46±6ng/L, 31±4ng/L vs 42±7ng/L, 28±4ng/L vs 40±5ng/L(all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groupsP>0.05. Conclusion sEsomeprazole combined with mosapride shows good clinical effect on reflux esophagitis. This therapy can significantly restore the levels of serum gastrin, pepsinogen and inflammatory factors without increasing adverse reactions.

copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭
Baidu
map